ViroMed moves ahead with diabetic neuropathy gene therapy
This article was originally published in Scrip
Executive Summary
Amid challenges elsewhere for gene therapies, South Korea's ViroMed has taken a step further into the US market for its biologics with the recent approval from the FDA to start a Phase III clinical study with its gene therapy for diabetic peripheral neuropathy (DPN).